Fig. 2From: Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccineSummary of local adverse events in the trial participants. Participants in indicated group experiencing indicated adverse events are shown. Asterisks show statistical difference between placebo arm based on Fisher’s exact test with Bonferroni correction (***p < 0.001)Back to article page